C
Chung-Han Lee
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 102
Citations - 4893
Chung-Han Lee is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 20, co-authored 68 publications receiving 2865 citations. Previous affiliations of Chung-Han Lee include Cornell University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged,Ying-Bei Chen,Andrea Knezevic,Jozefina Casuscelli,Almedina Redzematovic,Renzo G. DiNatale,Maria I. Carlo,Chung-Han Lee,Darren R. Feldman,Sujata Patil,A. Ari Hakimi,Paul Russo,Robert J. Motzer,Martin H. Voss +13 more
TL;DR: Metastatic ChRCC patients with SF had worse outcomes compared with those without SF, and median TTR < 3 months for this subgroup supports close surveillance after nephrectomy for localized tumors.
Journal ArticleDOI
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
Maria I. Carlo,Joshua Chaim,Sujata Patil,Yelena Kemel,Alison M. Schram,Kaitlin M. Woo,Devyn Taylor Coskey,Gouri Nanjangud,Martin H. Voss,Darren R. Feldman,James J. Hsieh,A. Ari Hakimi,Ying-Bei Chen,Robert J. Motzer,Chung-Han Lee +14 more
TL;DR: In this paper, the authors report on clinical outcomes with systemic therapy and characterize molecular features of renal medullary carcinoma (RMC) using a retrospective analysis on 36 patients given a pathologic diagnosis at one institution from 1995 to 2015.
Journal ArticleDOI
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack Patrick Gleeson,Ines Nikolovski,Renzo G. DiNatale,Mark Zucker,Andrea Knezevic,Sujata Patil,Yasser Ged,Ritesh Kotecha,Natalie Shapnik,Samuel Murray,Paul Russo,Jonathan A. Coleman,Chung-Han Lee,Zsofia K. Stadler,A. Ari Hakimi,Darren R. Feldman,Robert J. Motzer,Ed Reznik,Martin H. Voss,Ying-Bei Chen,Maria I. Carlo +20 more
TL;DR: In this article, the authors studied clinical and genomic characteristics of Fumarate hydratase-deficient renal cell carcinoma (RCC), including response to systemic therapies and next-generation sequencing (NGS).
Journal ArticleDOI
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
Chung-Han Lee,Amishi Yogesh Shah,James J. Hsieh,Arpit Rao,Alvaro Pinto,Mehmet Asim Bilen,Allen Lee Cohn,Christopher Di Simone,David R. Shaffer,Regina Gironés Sarrió,Sara Gunnestad Ribe,Jane Wu,Emmett V. Schmidt,Rodolfo F. Perini,Peter Kubiak,Alan D. Smith,Robert J. Motzer +16 more
TL;DR: LEN, a multikinase VEGFR inhibitor, plus everolimus is approved for advanced RCC after prior VEGF-targeted therapy and PEMBRO, an anti-PD-1 antibody, plus axitinib is approved as first-line RCC treatment.
Journal ArticleDOI
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Maria I. Carlo,Brandon J. Manley,Sujata Patil,Kaitlin M. Woo,Devyn Taylor Coskey,Almedina Redzematovic,Maria E. Arcila,M. Ladanyi,William Lee,Ying-Bei Chen,Chung-Han Lee,Darren R. Feldman,A.A. Hakimi,Robert J. Motzer,James J. Hsieh,Martin H. Voss +15 more
TL;DR: Genomic alterations in ccRCC tumors have prognostic implications in patients with metastatic disease, and BAP1 and TERT promoter mutations may be present in higher frequency than previously thought.